Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ESMO 2026 | Keeping pace with emerging biomarkers across complex sarcoma subtypes

Joanna Szkandera, MD, Medical University of Graz, Graz, Austria, comments on the challenges of keeping up with the rapid development of new biomarkers in sarcomas, with pathologists identifying new fusions and mutations that currently lack targeted therapies. Due to the complexity of sarcoma subtypes, with 187 different subtypes according to the new WHO classification, reliable biomarkers are scarce, except for a few examples like NTRK fusions. This interview took place at the European Society for Medical Oncology (ESMO) 2026 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Transcript

I think it’s a very, very important question and step, but the problem is that the pathologists are already much ahead of us. So they are defining a lot of new fusions, for example, or mutations, which in practice we still cannot target. So the pharmaceutical industry, of course, needs to adapt to this very quick development. And for us, we have, according to the new WHO classification, we have 187 different subtypes...

I think it’s a very, very important question and step, but the problem is that the pathologists are already much ahead of us. So they are defining a lot of new fusions, for example, or mutations, which in practice we still cannot target. So the pharmaceutical industry, of course, needs to adapt to this very quick development. And for us, we have, according to the new WHO classification, we have 187 different subtypes. So as you can imagine, in these classifications, there are also subtypes with different fusions, and we do not know the significance of many of them. So unfortunately, in sarcomas, we do not have really biomarkers that are available which we can rely on. There are some, like for example, NTRK fusions, where we of course know how to target it with the available drugs and we know which response rates are going to be expected, but unfortunately, it’s a very, very new field to first discover all the possibilities we have and then to try to cover them with the according drugs or even to find biomarkers so that we can select our patients, because this, of course, is one of the most important points, to select the right patients to receive the right therapy and not put all of them in one basket and treat them in the same way.

This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.

Read more...

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.